ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration

Cancer Research

Volumn 62, Issue 16, 2002, Pages 4645-4655

  Wedge, Stephen R ^a   Ogilvie, Donald J ^a   Dukes, Michael ^a   Kendrew, Jane ^a   Chester, Rosemary ^a   Jackson, Janet A ^a   Boffey, Sarah J ^a   Valentine, Paula J ^a   Curwen, Jon O ^a   Musgrove, Helen L ^a   Graham, George A ^a   Hughes, Gareth D ^a   Thomas, Andrew P ^a   Stokes, Elaine S E ^a   Curry, Brenda ^a   Richmond, Graham H P ^a   Wadsworth, Peter F ^a   Bigley, Alison L ^a   Hennequin, Laurent F ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [(1 METHYL PIPERIDIN 4 YL)METHOXY]QUINAZOLIN 4 AMINE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH; XENOGRAFT;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; FEMALE; HUMANS; LYMPHOKINES; MALE; MICE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PIPERIDINES; QUINAZOLINES; RATS; RATS, WISTAR; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037102369     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Vascular permeability factor, an endothelial cell mitogen related to PDGF
2. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro
3. Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis
4. Isolation of putative progenitor endothelial cells for angiogenesis
5. In vitro differentiation of endothelial cells from AC133-positive progenitor cells
6. Focal vascular endothelial growth factor correlates with angiogenesis in human endometrium. Role of intravascular neutrophils
7. Selective ablation of immature blood vessels in established human tumours follows vascular endothelial growth factor withdrawal
8. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis
9. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
10. Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions
11. Vascular permeability factor/vascular endothelial growth factor: An important mediator of angiogenesis in malignancy and inflammation
12. Vascular endothelial growth factor increases Rana vascular permeability and compliance by different signalling pathways
13. Angiogenesis in cancer and other diseases
14. Angiogenesis in cancer, vascular, rheumatoid and other disease
15. Angiogenesis and vascular regression in the ovary
16. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation
17. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularisation
18. Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularisation
19. Vascular endothelial growth factor and glioma angiogenesis: Coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms
20. Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells
21. Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements
22. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression
23. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity
24. Mutant ras oncogenes up-regulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
25. Down-regulation of vascular-endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src
26. The protein tyrosine kinase family of the human genome
27. Signaling via vascular endothelial growth factor receptors
28. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development
29. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
30. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
31. Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers
32. 121
33. Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes
34. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells
35. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinase
36. Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively
37. Analysis of biological effects and signalling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2)
38. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
39. Technology evaluation: IMC-1C11. ImClone Systems
40. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
41. Novel 4-anilinoquinazolines with C-7 basic side chains. Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors
42. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors
43. Production of the angiogenic factors VEGF and bFGF at tumour sites may also confer an acute haemodynamic advantage to the tumour
44. Investigation of tumor angiogenesis in an id mouse model: Role of host tumor interactions
45. Assays for angiogenesis: A review
46. Hemodynamic effects of intracoronary VEGF delivery: Evidence of tachyphylaxis and NO dependence of response
47. Immunolocalisation of vascular endothelial growth factor (VEGF) in human neonatal growth plate cartilage
48. Different signal transduction properties of KDR and Flt-1: Two receptors for vascular endothelial growth factor
49. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells
50. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice
51. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
52. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
53. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors
54. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer
55. Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma
56. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium
57. Acidic and basic FGFs dilate arterioles of skeletal muscle through a NO-dependent mechanism
58. Angiogenesis and bone growth
59. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation
60. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state
61. The epidermal growth factor receptor and its inhibition in cancer therapy
62. Epidermal growth factor-related peptides and their receptors in human malignancies
63. Role of EGF receptor tyrosine kinase activity in antiapoptotic effect of EGF on mouse hepatocytes
64. Epidermal growth factor receptor signalling and the invasive phenotype of ovarian carcinoma cells
65. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD 1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
66. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
67. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
68. Selective increase of α2-integrin sub-unit expression on human carcinoma cells upon EGF-receptor activation
69. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
70. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors
71. Structure activity relationship and in vivo efficacy of indole-quinazolines, a novel series of selective and orally active inhibitors of VEGF receptor tyrosine kinase activity (Flt-1 and KDR)
72. Vascular endothelial factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
73. Phase I pharmacokinetic and biological study of the angiogenesis inhibitor, ZD6474, in patients with solid tumors